TY - JOUR

T1 - Breast cancer therapy and cardiovascular risk

T2 - focus on trastuzumab

AU - Sandoo, Aamer

AU - Kitas, George D

AU - Carmichael, Amtul R

PY - 2015/4/7

Y1 - 2015/4/7

N2 - Breast cancer is the most common cancer in the UK. Advances in the methods of early diagnosis as well as newer and more effective treatments have led to improvements of disease-free and overall survival over the last decade. Almost one-third of breast cancers present with an aggressive form characterized by increased expression of human epidermal growth receptor 2 (HER2) proteins. A targeted treatment using monoclonal antibodies against HER2 expression such as trastuzumab has been shown to improve survival. Unfortunately, there is a degree of cardiotoxicity associated with these agents, as inhibition of HER2 pathways can also impair cardioprotective pathways. In the present review, we discuss the mechanisms by which trastuzumab might affect vascular homeostasis leading to endothelial dysfunction. We also provide suggestions for future research examining the effects of trastuzumab on the vasculature in breast cancer.

AB - Breast cancer is the most common cancer in the UK. Advances in the methods of early diagnosis as well as newer and more effective treatments have led to improvements of disease-free and overall survival over the last decade. Almost one-third of breast cancers present with an aggressive form characterized by increased expression of human epidermal growth receptor 2 (HER2) proteins. A targeted treatment using monoclonal antibodies against HER2 expression such as trastuzumab has been shown to improve survival. Unfortunately, there is a degree of cardiotoxicity associated with these agents, as inhibition of HER2 pathways can also impair cardioprotective pathways. In the present review, we discuss the mechanisms by which trastuzumab might affect vascular homeostasis leading to endothelial dysfunction. We also provide suggestions for future research examining the effects of trastuzumab on the vasculature in breast cancer.

KW - Antineoplastic Agents

KW - Breast Neoplasms

KW - Endothelium, Vascular

KW - Genes, erbB-2

KW - Heart Failure

KW - Homeostasis

KW - Humans

KW - Oxidative Stress

KW - Reactive Oxygen Species

KW - Trastuzumab

KW - Journal Article

KW - Review

U2 - 10.2147/VHRM.S69641

DO - 10.2147/VHRM.S69641

M3 - Review article

C2 - 25897242

VL - 11

SP - 223

EP - 228

JO - Vascular health and risk management

JF - Vascular health and risk management

SN - 1176-6344

ER -